A. A. Kuryndina

A. A. Kuryndina

Auto-generated profile, based on publicly available information

A. A. Kuryndina

Ural State Medical University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2022 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
NIN. V. Izmozherova
N. V. Izmozherova
APA. A. Popov
A. A. Popov
AKA. A. Kuryndina
A. A. Kuryndina
EGE. I. Gavrilova
E. I. Gavrilova
MSM. A. Shambatov
M. A. Shambatov
VBV. M. Bakhtin
V. M. Bakhtin
Aim. Assessment of the level and structure of polymorbidity, features of pharmacotherapy therapy in patients of different age groups, belonging to the category of high and extremely high cardiovascular risk, observed in outpatient clinics.Material and methods. The single-stage study included 282 patients of high and very high cardiovascular risk who were divided into three groups: (1) age 45-59 years, (2) 60-74 years, (3) ≥75 years. The structure of polymorbidity and features of pharmacotherapy in different age groups patients were evaluated. The frequency of polypragmasia was determined, and treatment adequacy in patients over 65 years of age was analyzed using the STOPP / START criteria and the Beers criteria of 2019.Results. High and very high cardiovascular risk patients have been found to be highly polymorbid, polimorbidity level increasing with age. Thus, among elderly patients, ischemic heart disease, chronic heart failure (CHF) were more often detected, as well as a high frequency of concomitant and background conditions, especially bone and joint system involvement (osteoarthritis, rheumatoid arthritis). Polypragmasia (administration of ≥5 drugs) was detected in 150 patients (53.2%) and was more common among elderly patients. According to Beers criteria, there were 48 cases of inadequate medication prescribing in 46 (28.0%) elderly patients. According to 80 STOPP criteria, 75 cases of prescribing potentially non-recommended drugs to 55 patients (32.1%) were detected. According to 34 START criteria, 116 cases of non-prescribing of necessary drugs to 52 (30.4%) elderly patients were found. When assessing the frequency of prognosis modifying medication prescribing, patients with CHF in 107 (63.0%) cases received angiotensin converting enzyme inhibitors, and in 42 cases (24.5%) angiotensin II receptor antagonists had been prescribed. Thus, 87.5% CHF patients were receiving renin-angiotensin-aldosterone system blockers. Statins were administered in 225 (79.8%) cases, antiplatelet agents were pre-scribed in 157 (67.9%) cases, and 23 persons (9.9%) were on oral anticoagulants for atrial fibrillation.Conclusion. In the structure of the studied cohort most of the high and very high cardiovascular risk outpatients were polimorbid, elderly and senile. Polypragmasia has been detected in more than half of elderly outpatients (53%), irrational medication was found in 28% to 30% elderly patients. Most patients with CHF were on statins, antithrombotic therapy, and renin-angiotensin-aldosterone system blockers.

2 March 2025 in Ural Medical Journal
Verified
Journal Article
Open access
PDF file
NIN. V. Izmozherova
N. V. Izmozherova
APA. A. Popov
A. A. Popov
AKA. A. Kuryndina
A. A. Kuryndina
EGE. I. Gavrilova
E. I. Gavrilova
MSM. A. Shambatov
M. A. Shambatov
VBV. M. Bakhtin
V. M. Bakhtin
Introduction. Arterial hypertension (AH) is the most common chronic non-communicable disease, especially among individuals over 60 years old, where its prevalence exceeds 60%. The relationship between blood pressure (BP) levels and the risk of cardiovascular events is observed across all age groups. The aim of the study was to assess the adequacy of antihypertensive therapy in outpatient multimorbid patients of different age groups.Materials and methods. The study included 323 outpatient patients with verified AH (92 men and 231 women). Patients were divided into three age groups: middle-aged, elderly, and old age. The frequency of achieving target BP levels, the structure of antihypertensive therapy, and the prescription of lipid-lowering and antiplatelet agents were evaluated.Results. The severity of AH did not differ between the groups. In the elderly groups, patients with high cardiovascular risk and comorbidities such as type 2 diabetes and osteoarthritis predominated. The most frequently prescribed medications were inhibitors of the renin-angiotensin-aldosterone system (94.1%). Target BP levels were mainly achieved due to systolic pressure (60%), while diastolic pressure was only controlled in 22% of cases.Discussion. The results are consistent with previous studies.Conclusion. AH in elderly patients is associated with high comorbidity and cardiovascular risk. Achieving target BP levels is possible with combination therapy, including renin-angiotensin-aldosterone system blockers and calcium antagonists. Additional treatment strategies are needed to reduce the residual risk of cardiovascular diseases.

1 November 2024 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
SVS. S. Vedenskaya
S. S. Vedenskaya
EVE. M. Vishneva
E. M. Vishneva
AKA. A. Kuryndina
A. A. Kuryndina
NTN. V. Tagiltseva
N. V. Tagiltseva
DID. A. Isakova
D. A. Isakova
OSO. G. Smolenskaya
O. G. Smolenskaya
Aim. To establish the relationship between lipid profile parameters, coagulation system and inflammation markers in patients with hypertension (HTN) and multifocal atherosclerosis (MFA).Material and methods. The study included 110 patients with HTN and MFA with a median age of 59 (51,0;64,3) years. Of these, 15 patients achieved target lowdensity lipoprotein cholesterol (LDL-C) 1,8 mmol/l (group 2). Patients in both groups received lipid-l owering and comparable antihypertensive, antiplatelet therapy. To identify coagulation disorders, a test was performed on the T-2 Thrombodynamics Analyser System (OOO GemaCor, Moscow, Russia). All study participants were assessed for levels of high-sensitivity C-reactive protein and interleukin-6.Results. Despite the lipid-l owering therapy, most patients with HTN and MFA (86,4%) did not achieve target LDL-C <1,8 mmol/l. In patients of group 2, compared to group 1, more pronounced procoagulant shifts were noted. The clot growth rate and the permanent clot growth rate were shifted to the hypercoagulation (28,6 μm/min vs 27 μm/min). Correlations between the studied parameters were also revealed. In group 1, the LDL-C level had a moderate direct correlation with the initial clot growth rate (r1=0,54, p1=0,04) and clot density (r1=0,55, p1=0,03), while in group 2, the concentrations of total cholesterol and LDL-C correlated with clot growth delay (r2=-0,22, p2=0,03 and r2=-0,21, p2=0,04, respectively).Conclusion. In patients with HTN and MFA, complex relationships between lipid parameters, coagulation parameters, and inflammatory markers are observed, especially in the group with unachieved lipid target levels. Extra efforts are needed to identify patients with HTN and MFA in clinical practice and to prescribe optimal lipid-lowering therapy. In addition to lipid parameters, correction of other disorders (hemostasis, inflammation) that may affect the prognosis is necessary.